Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed <i>M. vaccae</i> administered daily for one month.

The proportions of patients who responded favorably, by either parameter, i.e., absolute weight and BMI, were 86% and 34.6% for V7 and placebo respectively, which was highly significant by Fisher's 2 × 2 contingency table ( P < 0.0001).

also in 132,142 other papers